| ||||||||||||||
|
|
|||||||||||||



*University of Ottawa Centre for Transfusion Research, Ottawa Hospital Research Institute, Clinical Epidemiology Unit;
Division of Hematology, London Health Sciences Centre, Ontario;
Department of Laboratory Medicine, McMaster University Health Centre;
Division of Cardiovascular Anaesthesiology, Institut de Cardiologie de Montreal; and ||Department of Pathology, Ottawa Hospital, Canada
Address correspondence and reprint requests to Paul C. Hébert, MD, Division of Hematology, London Health Sciences Centre, London, Ontario, Canada. Address e-mail to phebert{at}ohri.ca.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
However, there are well-defined biochemical and corpuscular changes to RBC during storage, collectively referred to as "the storage lesion" (13). These changes include a depletion of adenosine triphosphate and 2,3-DPG, membrane vesiculation (46), lipid peroxidation of cell membranes (7), and loss of deformability (8,9).1 During RBC storage, changes to the storage medium occur, including a progressive decrease in pH, an increase in plasma potassium, release of free hemoglobin from lysed RBC (10), and the generation of cytokines and other bioreactive substances (1115). The clinical consequences of transfusing modified corpuscle and storage by-products are unknown (1619). If prolonged storage truly does render RBC ineffective, then critically ill patients and patients undergoing cardiac surgical procedures may well experience negative clinical consequences from prolonged RBC storage. Despite these concerns, regional and hospital blood banks have developed inventory management strategies based upon minimizing blood wastage because of outdating of products because the benefits of fresh blood remain theoretical. As a consequence, patients in major centers often receive older products to ensure its use.
Given that we were unsure if blood banks could meet transfusion requirements for fresh RBC, we evaluated compliance with a strategy that would provide RBC stored <8 days. We also undertook a preliminary evaluation of major clinical consequences in cardiovascular surgical and critically ill patients who receive at least one RBC unit in the course of their care.
| Methods |
|---|
|
|
|---|
Patients were randomly allocated to receive either RBC stored for <8 days or standard issue RBC. The standard therapy group received RBC issued from the hospital blood bank with the longest storage times first in accordance to standard blood bank procedure. To ensure the maximum age separation between groups, we only allocated patients on days when the average age of RBC in the blood bank exceeded 15 days. The experimental group received RBC that were stored <8 days from the day of collection. This time interval represented a compromise between feasibility and having a product that would still be considered fresh. Once randomized, age-specific RBC were transfused during the patients entire hospital stay up to 30 days. All clinical management decisions, including the decision to administer transfusions, remained at the discretion of the attending team. The use of other blood products and alternatives to RBC transfusions, such as cell salvage and medications, were not controlled but recorded.
Randomization was initiated by a telephone request from the attending team for a RBC transfusion. Upon receipt of a request for RBC, a blood bank technologist who was not involved in clinical care opened a sequentially numbered sealed opaque envelope. As a consequence, concealment of randomization and blinding of the study interventions were ensured. The randomization schedule consisted of a computer-generated random listing of the two treatment allocations blocked into groups of four and six and stratified by center and categories of cardiac surgery or critical care. An independent statistician prepared the listing. A patient was considered randomized once requested RBC were issued by the local blood banks.
Canadian Blood Services or Héma Québec supplied all RBC products administered in this study. Both organizations produced RBC by collecting whole blood into CPD-2 anticoagulant. The platelet-rich plasma was removed, and then 100 mL of AS-3 (NutricelTM, ProNature Laboratories) was added. The blood providers reported that RBC units had the following characteristics: an average volume of 300 mL; a hematocrit of 65%; and an average storage time of 14 days, ranging from region to region and according to use and blood procurement. All blood products had undergone universal prestorage leukoreduction using either the Leukotrap-RC or the Leukotrap WB in-line systems (Pall Medical, Blood Processing Group, East Hills, NY). Leukofiltration using these systems reduced white blood cell content of a unit of RBC from an average of 3.0 x 109/unit to 2.5 x 105/unit, a decrease of 4 logs.
We evaluated compliance to treatment strategies by determining the availability and administration of predefined RBC products. Patients were considered compliant to protocol if 90% or more of transfused RBC were stored 8 days or less in the experimental group or more than 15 days in the control group. To maximize our ability to detect a difference in a small trial, we grouped hospital mortality, serious nosocomial infections, and thrombotic events including myocardial infarctions and acute ischemic strokes into a predefined composite outcome. Myocardial infarction was defined as new q waves in two consecutive leads on electrocardiography or a fivefold increase in serum troponin or the MB fraction of serum creatine kinase (20), whereas cerebrovascular accidents were defined as new focal neurological deficit lasting more than 24 h confirmed by a neurologist or new deficit on an imaging study reference (21,22). Specific nosocomial infections considered in the definition were pneumonia, surgical wound infections including mediastinitis and osteomyelitis, and bacteremia from organisms not considered normal skin flora. Definitions for all infections were based upon the Centers for Disease Control criteria (23). As secondary clinical outcomes, we examined the number of organ failures combined with death assessed using the score by Hebert et al. (24,25). Finally, we examined the intensity of interventions including respiratory support, defined as the number of days on mechanical ventilation; intensity of cardiovascular support, defined as the number of days requiring vasoactive drugs, an aortic balloon pump, or ventricular assist device; and the intensity of renal support by measuring the number of days of renal replacement therapy.
The sample size was arbitrarily established at 1520 patients per center in this pilot. A total sample size approximating 70 patients would allow us to estimate adherence rates within each group with 95% confidence intervals (CI) of ±3.5% if the compliance rate approximated 90%. For a composite clinical outcome, a difference between groups of 50% would have a 95% CI of ±12%.
Our primary analysis was based upon treatment received given that most of the reasons for not receiving RBC were related to inadequate implementation of study procedures at a single site. Compliance rates were established for each group followed by calculations of 95% CI and compared using a
2 statistic. RBC storage times were described by calculating median values and interquartile ranges for all RBC products transfused within each group once randomized during the entire hospital stay. To demonstrate a significant separation in storage times using standard RBC as a control, we compared median differences in storage time using a Wilcoxon rank sum test statistic. The composite measure, including major adverse clinical consequences, was contrasted using a
2 statistic. We explored the influence of comorbid illnesses (presence or absence), major diagnostic grouping (cardiac surgery and critical care), and center (four centers) using stratified analyses and logistic regression models with the composite measure as the dependent variable. Outcomes related to the intensity and type of care received such as lengths of hospital and ICU stay, the number of days of mechanical ventilation, vasoactive drug use, and dialysis were compared using the Wilcoxon rank sum test. We reported all P values as two-tailed, without corrections for multiple comparisons.
| Results |
|---|
|
|
|---|
|
Overall, 73% of patients received RBC with storage times that corresponded to the treatment allocation more than 90% of the time. The compliance target of 90% was attained by 91% of patients allocated to the group receiving RBC stored 8 days or less versus 59% of patients in the standard group (P = 0.008). The median storage time was 4 days in the experimental group compared to 19 days in the standard group, a median difference of 15 days (interquartile range, 1216 days; P < 0.001)(Fig. 1).
|
For all randomized patients (n = 66), 24% (n = 7) of patients in the experimental group either died or had a life-threatening complication, the composite outcome, as compared to 15% (n = 5) in the standard group (risk difference of 0.09; 95% CI, 0.100.28; P = 0.35). If we considered all patients transfused (including two crossovers), then the proportion of patients with the composite outcome was 27% (n = 7) in the experimental group compared to 12% in the control group (risk difference of 0.15; 95% CI, 0.060.35; P = 0.19). In considering only the 57 patients who received age-appropriate RBC, the proportion of patients with the composite outcome was 27% versus 12% in the experimental versus control groups, respectively (risk difference of 0.14; 95% CI, 0.070.35; P = 0.31) (Table 2). While in the hospital, there were five deaths observed in the experimental group and three in the standard group (P = 0.45). There were no reported bacteremia, deep incisional infections, endocarditis, or mediastinitis reported in either group. No patients had a cerebral hemorrhage, whereas three patients in the experimental group had a postoperative myocardial infarction, and one patient in the same group had an acute ischemic neurologic event. The stratified analysis or logistic regression did not detect any clinically or statistically important changes in the odds of having an adverse clinical outcome as a composite measure.
|
| Discussion |
|---|
|
|
|---|
A number of considerations related to feasibility arose before and during this study. Before the enrollment of patients, we developed a detailed description of blood bank procedures at each institution focused on ensuring a supply of RBC stored less than eight days (inventory management considerations), distribution of the appropriate product (allocation and distribution considerations), and considerations related to the identification of patients with a very high or definitive probability of requiring RBC. Despite these many procedures, seven patients who were considered randomized were not transfused RBC. In this instance, patients were issued RBC by the blood bank at the request of the attending anesthesiologist in response to anticipated blood loss during surgical interventions. Fortunately, the decision to withhold a transfusion was not based upon group assignment. This concern arose early in the trial and was remedied by providing assurances to clinicians that RBC would be delivered within minutes of the request. The blood bank use of rapid intraoperative randomization based on a transfusion decision creates a number of logistical challenges. Study maneuvers such as pretesting of interventions at each site, a rapid call back of blood products issued by local blood banks, and availability of point-of-care hemoglobin measurements may all enhance the decision process thereby minimizing the number of RBC requests but not transfused. Early attention to study procedures, such as ensuring the availability of cross-matched fresh RBC, would also have potentially avoided the two crossovers, a rate still considered acceptable in a large clinical trial.
Although we were unable to detect meaningful clinical benefits from the transfusion of RBC stored for less than eight days, we believe that prolonged RBC storage should be further evaluated in laboratory and clinical studies. This view was shared by the authors (26) of an editorial accompanying the only other randomized controlled trial (RCT) evaluating storage times. In the only other published RCT, Walsh et al. (27) evaluated changes in gastric intramucosal pH (pHi), a measure of gastric perfusion, in 22 mechanically ventilated critically ill patients who required a RBC transfusion. In this study, the authors were not able to detect any adverse consequences on pHi and changes in the arterial-gastric mucosal CO2 gap with a storage time exceeding 20 days compared with patients receiving RBC less than five days old. These results contradicted earlier observations in a before and after study conducted by Marik and Sibbald (28) who documented an inverse relationship between the age of transfused RBC and gastric pHi (r = 0.71; P < 0.001).
A number of retrospective clinical studies have documented an association between prolonged storage times and adverse clinical outcomes including mortality (29), pneumonia (30), serious infections (31), and length of stay (32) in many patient populations including multiple trauma victims, critically ill patients, and patients undergoing cardiac surgical procedures. Unfortunately, all retrospective studies evaluating prolonged RBC storage will invariably be subject to the confounding influences of factors such as the number of RBC units transfused, the mixture of storage times from the multiple units transfused throughout a hospital stay, and patient factors, including severity of illness. Inferences related to the clinical consequences of transfusing RBC with a storage time less than eight days were limited by a small sample size and imbalances and clinically important imbalances in baseline characteristics.
In summary, we documented that a larger trial would be feasible but would require significant attention to the adequacy of the RBC supply during the trial, randomization concerns, and crossovers. In addition, given the costs of adapting the collection and distribution process within blood systems, absolute differences in major outcomes such as mortality, organ failure, and infections less than 3%4% between RBC with short storage times and standard issue RBC may not be worth pursuing. At this time, there is insufficient evidence to make any recommendations regarding the transfusion of RBC stored for eight days or less in patients considered at high risk of adverse consequences from blood transfusions.
| Footnotes |
|---|
Accepted for publication October 11, 2004.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Rigamonti, A. T. McLaren, C. D. Mazer, K. Nix, T. Ragoonanan, J. Freedman, A. Harrington, and G. M. T. Hare Storage of strain-specific rat blood limits cerebral tissue oxygen delivery during acute fluid resuscitation Br. J. Anaesth., March 1, 2008; 100(3): 357 - 364. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Weber, N. Jabbour, and R. C. G. Martin II Anemia and Transfusions in Patients Undergoing Surgery for Cancer Ann. Surg. Oncol., January 1, 2008; 15(1): 34 - 45. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|